

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7041056

SUBMISSION TYPE:	CORRECTIVE ASSIGNMENT
NATURE OF CONVEYANCE:	Corrective Assignment to correct the NAME OF THE ASSIGNEE previously recorded on Reel 047941 Frame 0921. Assignor(s) hereby confirms the THE NAME OF THE ASSIGNEE IS "IMPACT THERAPEUTICS (SHANGHAI), INC".
CONVEYING PARTY DATA	
Name	Execution Date
SUIXIONG CAI	09/27/2018
PING HUANG	09/26/2018
RECEIVING PARTY DATA	
Name:	IMPACT THERAPEUTICS (SHANGHAI), INC
Street Address:	ROOM 603, NO. 3 BUILDING, 111 XIANGKE ROAD
Internal Address:	CHINA (SHANGHAI) PILOT FREE TRADE ZONE
City:	SHANGHAI
State/Country:	CHINA
Postal Code:	201210
PROPERTY NUMBERS Total: 1	
Property Type	Number
Patent Number:	10562889
CORRESPONDENCE DATA	
Fax Number:	(202)371-2540
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	2023712600
Email:	resmond@sternekessler.com, deniseb@sternekessler.com
Correspondent Name:	STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
Address Line 1:	1100 NEW YORK AVENIUE, NW
Address Line 4:	WASHINGTON, D.C. 20005
ATTORNEY DOCKET NUMBER:	3386.0080001
NAME OF SUBMITTER:	ROBERT W. ESMOND
SIGNATURE:	/Robert W. Esmond, #32,893/
DATE SIGNED:	11/24/2021
Total Attachments: 5	
source=Corrective-Assignment-3386-0080001#page1.tif	

source=Corrective-Assignment-3386-0080001#page2.tif

source=Corrective-Assignment-3386-0080001#page3.tif

source=Corrective-Assignment-3386-0080001#page4.tif

source=Corrective-Assignment-3386-0080001#page5.tif

PATENT

REEL: 058237 FRAME: 0386

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5316538

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
SUIXIONG CAI	09/27/2018
PING HUANG	09/26/2018
RECEIVING PARTY DATA	
Name:	IMPACT THERAPEUTICS, INC.
Street Address:	ROOM 603, NO. 3 BUILDING, 111 XIANGKE ROAD
Internal Address:	CHINA (SHANGHAI) PILOT FREE TRADE ZONE
City:	SHANGHAI
State/Country:	CHINA
Postal Code:	201210
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16089486
CORRESPONDENCE DATA	
Fax Number:	(202)371-2540
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	202-371-2600
Email:	selmer@sternekessler.com, lmiller@sternekessler.com
Correspondent Name:	STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
Address Line 1:	1100 NEW YORK AVENUE, NW
Address Line 4:	WASHINGTON, D.C. 20005
ATTORNEY DOCKET NUMBER:	3386.0080001
NAME OF SUBMITTER:	STEPHANIE L. ELMER
SIGNATURE:	/Stephanie L. Elmer, #59244/
DATE SIGNED:	01/09/2019
Total Attachments: 4	
source=3386.0080001 - assignment#page1.tif	
source=3386.0080001 - assignment#page2.tif	
source=3386.0080001 - assignment#page3.tif	
source=3386.0080001 - assignment#page4.tif	

ASSIGNMENT

In consideration of the sum of One Dollar (\$1.00) or equivalent and other good and valuable consideration paid to each of the undersigned inventors: **Suixiong CAI** and **Ping HUANG**, hereby sell and assign to ***IMPACT THERAPEUTICS, INC.**, a corporation formed under the laws of China, whose mailing address is Room 603, No. 3 Building, 111 Xiangke Road, China (Shanghai) Pilot Free Trade Zone, Shanghai, China 201210 (hereafter referred to as the Assignee), his/her entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages, for the United States of America (as defined in 35 U.S.C. § 100) and throughout the world,

***IMPACT THERAPEUTICS (SHANGHAI), INC**

(a) in the invention(s) known as **PROCESS FOR THE PREPARATION OF 1-(ARYLMETHYL)QUINAZOLINE-2,4(1H,3H)-DIONES** for which

application(s) for patent in the United States of America has a filing date or a 371(c) date of September 28, 2018 (also known as United States Application No. 16/089,486, which is the U.S. national phase of International Application No. PCT/CN2017/078913, International Filing Date March 31, 2017), in any and all applications thereon, in any and all Letters Patent(s) therefor, and

(b) in any and all applications that claim the benefit of the patent application listed above in part (a), including non-provisional applications, continuing (continuation, divisional, or continuation-in-part) applications, reissues, extensions, renewals and reexaminations of the patent application or Letters Patent therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and

(c) in any and all inventions described in the patent application listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the undersigned inventors had this assignment and sale not been made.

The undersigned inventors agree to execute all papers necessary in connection with the application(s) and any non-provisional, continuing (continuation, divisional, or continuation-in-

PATENT

REEL: 058237 FRAME: 0388

part), reissue, reexamination or corresponding application(s) thereof and also to execute separate assignments in connection with such application(s) as the Assignee may deem necessary or expedient.

The undersigned inventors agree to execute all papers necessary in connection with any judicial or administrative proceeding, including but not limited to an interference, derivation, post-grant proceeding, or patent enforcement action (judicial or otherwise) related to the application(s) or any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof or Letters Patent(s) therefor and to cooperate with the Assignee in every way possible in obtaining evidence and assisting with such judicial or administrative proceeding.


The undersigned inventors hereby represent that he/she has full right to convey the entire interest herein assigned, and that he/she has not executed, and will not execute, any agreement in conflict therewith.

The undersigned inventors hereby grant the patent practitioners associated with **CUSTOMER NUMBER 26111** the power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

The undersigned inventors hereby represent that he/she understands that the patent practitioners associated with **CUSTOMER NUMBER 26111** are the legal representatives of, and attorneys for, the assignee, and are NOT the legal representatives of, and attorneys for, the inventors.

IN WITNESS WHEREOF, executed by the undersigned inventors on the date opposite his/her name.

Date: 9/27/2018

Signature of Inventor: 
Suixiong CAI

Date: _____

Signature of Inventor: _____
Ping HUANG

10108067_1.docx

ASSIGNMENT

In consideration of the sum of One Dollar (\$1.00) or equivalent and other good and valuable consideration paid to each of the undersigned inventors: **Suixiong CAI** and **Ping HUANG**, hereby sell and assign to ***IMPACT THERAPEUTICS, INC.**, a corporation formed under the laws of China, whose mailing address is Room 603, No. 3 Building, 111 Xiangke Road, China (Shanghai) Pilot Free Trade Zone, Shanghai, China 201210 (hereafter referred to as the Assignee), his/her entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages, for the United States of America (as defined in 35 U.S.C. § 100) and throughout the world,

*IMPACT THERAPEUTICS (SHANGHAI), INC

(a) in the invention(s) known as **PROCESS FOR THE PREPARATION OF 1-(ARYLMETHYL)QUINAZOLINE-2,4(1H,3H)-DIONES** for which application(s) for patent in the United States of America has a filing date or a 371(c) date of September 28, 2018 (also known as United States Application No. 16/089,486, which is the U.S. national phase of International Application No. PCT/CN2017/078913, International Filing Date March 31, 2017), in any and all applications thereon, in any and all Letters Patent(s) therefor, and

(b) in any and all applications that claim the benefit of the patent application listed above in part (a), including non-provisional applications, continuing (continuation, divisional, or continuation-in-part) applications, reissues, extensions, renewals and reexaminations of the patent application or Letters Patent therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and

(c) in any and all inventions described in the patent application listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the undersigned inventors had this assignment and sale not been made.

The undersigned inventors agree to execute all papers necessary in connection with the application(s) and any non-provisional, continuing (continuation, divisional, or continuation-in-

PATENT

REEL: 058237 FRAME: 0390

part), reissue, reexamination or corresponding application(s) thereof and also to execute separate assignments in connection with such application(s) as the Assignee may deem necessary or expedient.


The undersigned inventors agree to execute all papers necessary in connection with any judicial or administrative proceeding, including but not limited to an interference, derivation, post-grant proceeding, or patent enforcement action (judicial or otherwise) related to the application(s) or any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof or Letters Patent(s) therefor and to cooperate with the Assignee in every way possible in obtaining evidence and assisting with such judicial or administrative proceeding.

The undersigned inventors hereby represent that he/she has full right to convey the entire interest herein assigned, and that he/she has not executed, and will not execute, any agreement in conflict therewith.

The undersigned inventors hereby grant the patent practitioners associated with **CUSTOMER NUMBER 26111** the power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

The undersigned inventors hereby represent that he/she understands that the patent practitioners associated with **CUSTOMER NUMBER 26111** are the legal representatives of, and attorneys for, the assignee, and are NOT the legal representatives of, and attorneys for, the inventors.

IN WITNESS WHEREOF, executed by the undersigned inventors on the date opposite his/her name.

Date: _____	Signature of Inventor: _____ Suixiong CAI
Date: <u>2018, 09, 26</u>	Signature of Inventor: <u></u> Ping HUANG

10108067_1.docx